Ignite Creation Date:
2024-05-05 @ 11:55 PM
Last Modification Date:
2024-10-26 @ 10:41 AM
Study NCT ID:
NCT01442948
Status:
COMPLETED
Last Update Posted:
2011-09-29
First Post:
2011-09-22
Brief Title:
CD16 Monocytes in Coronary Heart Disease CHD
Sponsor:
Martin-Luther-Universität Halle-Wittenberg
Organization:
Martin-Luther-Universität Halle-Wittenberg
Study Overview
Official Title:
CD16 Monocytes in Patients With Coronary Heart Disease
Status:
COMPLETED
Status Verified Date:
2011-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PHAMOS
Brief Summary:
Monocytes may be separated into phenotypically and functionally distinct cell types by the presence or absence of the lipopolysaccharide receptor CD14 and the Fcγ-receptor CD16 The investigators hypothesize that the total numbers of CD16 monocytes are significantly related to cardiovascular outcome in patients with angiographically proven coronary heart disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None